14-day Premium Trial Subscription Try For FreeTry Free
$0.387
+0.0023 (+0.597%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.322 $0.440 Friday, 3rd May 2024 GLMD stock ended at $0.387. This is 0.597% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 8.84% from a day low at $0.367 to a day high of $0.399.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
Mar 30, 2023 $0.460 $0.470 $0.380 $0.470 30 540
Mar 29, 2023 $0.410 $0.450 $0.370 $0.450 118 932
Mar 28, 2023 $0.430 $0.450 $0.400 $0.429 13 646
Mar 27, 2023 $0.400 $0.425 $0.380 $0.400 17 557
Mar 24, 2023 $0.440 $0.440 $0.414 $0.420 3 777
Mar 23, 2023 $0.414 $0.440 $0.414 $0.435 8 393
Mar 22, 2023 $0.420 $0.420 $0.414 $0.414 20 418
Mar 21, 2023 $0.421 $0.440 $0.421 $0.430 40 645
Mar 20, 2023 $0.468 $0.470 $0.415 $0.440 30 591
Mar 17, 2023 $0.467 $0.470 $0.453 $0.468 13 296
Mar 16, 2023 $0.457 $0.481 $0.454 $0.468 25 667
Mar 15, 2023 $0.412 $0.467 $0.370 $0.467 14 841
Mar 14, 2023 $0.470 $0.470 $0.371 $0.431 56 300
Mar 13, 2023 $0.465 $0.475 $0.465 $0.470 47 247
Mar 10, 2023 $0.460 $0.470 $0.450 $0.450 34 533
Mar 09, 2023 $0.494 $0.490 $0.460 $0.460 66 984
Mar 08, 2023 $0.491 $0.500 $0.459 $0.470 50 311
Mar 07, 2023 $0.510 $0.510 $0.490 $0.500 14 386
Mar 06, 2023 $0.493 $0.540 $0.491 $0.520 32 573
Mar 03, 2023 $0.501 $0.520 $0.497 $0.520 19 267
Mar 02, 2023 $0.498 $0.520 $0.475 $0.497 23 977
Mar 01, 2023 $0.470 $0.500 $0.470 $0.470 14 228
Feb 28, 2023 $0.550 $0.550 $0.480 $0.480 12 250
Feb 27, 2023 $0.450 $0.548 $0.450 $0.527 49 644
Feb 24, 2023 $0.550 $0.560 $0.490 $0.539 88 668
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Golden Star

Ticker Date Change Price
BSCQ Apr 30 0.393% $19.09
EQC Apr 30 1.76% $18.72
HRB Apr 30 1.69% $47.23
REG Apr 30 1.35% $59.22
INGR Apr 30 0.576% $114.59
BSJP Apr 29 0.175% $22.91
LYG Apr 29 0.781% $2.56
ORA Apr 29 3.46% $64.48
DHT Apr 24 4.34% $11.28
LPLA Apr 19 2.62% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT